While it is okay to skip a beat in excitement, it is alarming when someone is prone to atrial fibrillation (Afib). Afib is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart-related complications, and according to a recent study, at least 2.7 million Americans are living with Afib. Moreover, the prediction in the healthcare sector states that by 2030 the number of Americans suffering from Afib will be 12.1 million. Left untreated, Afib can have serious health consequences. Untreated Afib causes an estimated 15 percent of the 700,000 strokes in the United States each year, while a person with Afib is five times more likely to have a stroke. Since the heart does not beat in the normal rhythm in an Afib patient, it allows blood to pool in the left atrial appendage (LAA).
For the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. Using its proprietary technologies, AtriCure has developed a family of products and cardiovascular devices that include: cardiac ablation devices used for procedures treating Afib patients, intra-operative testing equipment, and devices used for occluding the LAA.
AtriCure passionately focuses on reducing global Afib epidemic and help the patients heal faster. “We take a ‘Patient First’ approach to address the health issues of Afib,” says Michael H. Carrel, President and CEO of AtriCure.
AtriCure passionately focuses on reducing global Afib epidemic and help the patients heal faster
The company leads rigorous clinical science to determine the safest and most effective approaches and treatments for Afib. The company’s Isolator Synergy Ablation System is the first and only medical device approved by the FDA for the treatment of long-standing, persistent Afib. Additionally, AtriCure’s AtriClip LAA Exclusion System products are the most widely used LAA management devices worldwide.
In addition to the Afib treatment technology, AtriCure also offers Maze IV, a TRAC-AF patient outcomes registry, for healthcare professionals. The TRAC-AF Registry is an online tool developed to assist surgeons, cardiologists, and electrophysiologists in accurately and efficiently collecting patient-specific data on ablation procedures, as well as patient outcomes. The tool was developed in collaboration with leading ablation physicians and nurses to be consistent with the HRS Expert Guidelines for Afib outcomes. Capturing data is simple as it does not require full-time data collection staff, but sophisticated enough to provide meaningful data analysis. The Maze IV is one of the leading comprehensive ablation registries that provide individual centers complete control over their data and outcomes reporting to ensure that no other treatment centers or sponsors can access patients’ medical data.
The company’s commitment to Afib education generates consistent, predictable practices, and better standards of care. AtriCure undertakes relentless innovation to reveal new ideas that improve the experience of providers and supports the care they deliver to each patient. The employees of AtriCure act with unwavering integrity and transparency in all of their processes. Currently, AtriCure is expanding into pain management therapies and increasing its investment in innovation, clinical science, and education to focus on improving lives for Afib patients worldwide.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: